Background
Malignant tumor metastasis is usually the leading cause of death in cancer patients [
1]. Breast cancer is a multistate tumor that often has fatal effects by metastasizing to distant organs, such as bones, lungs, and liver [
2‐
4]. In light of this, it is critical to understand the regulatory mechanisms driving breast cancers (BrCas) metastasis and discover new therapeutic targets.
As one of the adhesion molecules related to tumor metastasis, CD44, a receptor of hyaluronan (HA), is becoming attractive for its role as a stem cell marker [
5,
6]. Until now, the function of CD44 in cancers is not fully understood, although data have proved that CD44 activities are usually triggered by binding with its ligands, especially HA. In fact, the interaction of receptors with ligands has always been a focus regarding the cellular behaviors under pathological processes, like inflammation, immune responses, wound healing and cancer progression [
7‐
9]. As HA is a non-sulfated glycosaminoglycan which usually binds with the multiple sites on the receptors that can cause CD44 linking together, we and other studies have found that CD44 cross-linking and de-crosslinking can deliver opposite signals to cells. Unfortunately, little is known about CD44 self-linking in breast malignancy.
CD44 cross-linking was initially described in rat pancreatic cancer cells, which can improve the ligand HA binding capacity [
10]. Subsequent researches showed that CD44 cross-linking has been associated with the progression of other human cancers. For example, in neuroblastoma cells, clusters of CD44 are located at the filamentous pseudopods and focal globular, which facilitate migration and invasion into the brain [
11]. CD44 clustering can also promote BrCas metastasis by relocating metalloproteinase-9 and up-regulating LFA-1 and VLA-4 [
12,
13]. However, most of the studies were conducted in a CD44 antibody-mediated cross-linking manner, so a model that naturally mimics the in vivo clustering of CD44 is urgently needed for cancer study. Our previous studies showed that high molecular weight HA can stimulate CD44 cross-linking in BrCas cells [
14] and the HA contents are more abundant in invasive BrCas cells [
15]. These prompted us to further investigate the role of HA dependent CD44 self-linking in BrCas progression and its underlying mechanisms.
In addition to CD44, the ERM proteins (Ezrin/Radixin/Moesin) [
16], which act as cross-linkers between the actin cytoskeleton and intracellular domain of CD44, have been implied in cell adhesion and motility [
17]. Among them, Moesin is particularly attractive for its curial role in organizing membrane domains and receptor signaling, as well as regulating the metastasis of tumor cells. Evidence has proved that CD44-Moesin interaction promotes human brain tumor proliferation by activating the Wnt signaling pathway [
18]. Other reports suggested that the expression of Moesin in glioma cells was significantly higher than that in normal astrocytes [
19] and there was a strong negative correlation with progression-free survival and overall survival [
20]. However, no role for Moesin activation in BrCas progression has been defined. Therefore, it is reasonable to speculate that CD44 receptors self-linking or aggregations are closely associated with the intracellular ERM molecules, and it is necessary to explore the regulating mechanism of ERM on CD44 interactions.
In this study,we aimed to determine the role of CD44 cross-linking on BrCas metastasis and explore the underlying mechanisms. We first analyzed the expression of CD44 cross-linking in BrCas cell lines, and elucidated the relations between CD44 clustering status and BrCas metastasis. Then, we investigated the effect of CD44 cross-linking on downstream ERM proteins. Our data showed that CD44 clustering could promote BrCas malignancy and disruption of CD44 clustering could dramatically inhibit cancer cell migration and invasion. Notably, phosphorylated Moesin (p-Moesin) may play an important role in CD44 cross-linking. These findings not only provide new mechanistic insights into CD44 cross-linking in BrCas but also indicate that p-Moesin may be a potential therapeutic target for treating invasive BrCas.
Materials and methods
Cell culture and antibodies
Human BrCas cell lines (MDA-MB-453, MCF-7, T-47D, MDA-MB-231, BT-549 and Hs-578t) were purchased from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). MDA-MB-453 cells were cultured in L-15(Gibco, USA), MCF-7 cells were cultured in MEM(Gibco, USA); BT-549 cells were cultured in RPMI-1640 medium(Gibco, USA); and MDA-MB-231, T-47D and Hs-578t cells were cultured in high-glucose DMEM (Gibco, USA).All the media were supplemented with 10% fetal bovine serum(Gibco, USA) and 100 IU/ml penicillin/streptomycin. Additional insulin with a final concentration of 0.01 mg/ml was added to the culture medium of BT-549 and Hs-578t. All cell lines were cultured at 37 °C in humidified air with 5% CO2 and 95% air. Primary antibodies against CD44 (Abcam, ab119348), CD44 (clone IM7, Cat #14-0441-86), ERM (CST, 3142S), p-ERM (CST, 3141S), Moesin (Abcam, ab52490) p-Moesin (Abcam, ab177943), p-Merlin(CST, 13281S), Merlin (CST, 12888) were used.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from cultured cells (MCF-7, T-47D, BT-549, and MDA-MB-231) by RNAiso Plus (Takara, Japan). RNA (1 μg) was reverse transcribed with the PrimeScript™ RT Reagent Kit with gDNA Eraser (Takara, Japan). Real-time PCR assays were performed by using SYBR Green Mix (Takara, Japan) according to the manufacturer’s protocol. All qRT-PCR values of each gene were normalized against that of GAPDH. The relative expression of genes was calculated by the 2−ΔΔCt method.
The primer sequences for qRT-PCR are: CD44-F: GACACCATGGACAAGTTTTGG, CD44-R: GACACCATGGACAAGTTTTGG; Moesin-F, ATGCCCAAAACGATCA GTGTG, Moesin-R: ACTTGGCACGGAACTTAAAGAG; Ezrin-F: ACCAATCAA TGTCCGAGTTACC, Ezrin-R: GCCGATAGTCTTTACCACCTGA; Radixin-F: AA TTGTGGCTAGGTGTTGATGC, Radixin-R: GGTGCCTTTTTGTCGATTGGC; Merlin-F: AGTGGCCTGGCTCAAAATGG, Merlin-R: TGTTGTGTGATCTCCTGA ACCA; GAPDH-F: AGCCTCAAGATCATCAGC, GAPDH-R: GAGTCCTTCCAC GATACC.
RNA interference
The shRNA-carrying lentiviruses against Moesin, and negative control were produced by Genechem (Shanghai, China). BT-549 and MDA-MB-231 cells were infected with concentrated virus according to the manufacturer’s protocol, and the expression of Moesin was validated by western blot analysis.
Western blotting
RIPA buffer (Beyotime, China) was used for protein extraction. After the total protein concentration was determined by a bicinchoninic acid protein assay kit (Sigma, USA), 30 μg protein samples were separated by 8% SDS polyacrylamide gels and transferred onto PVDF membranes(Millipore, Billerica, USA). The membrane was blocked with 5% nonfat milk in TBST for 1 h and incubated with the indicated antibody at 4 °C overnight. Then HRP-conjugated secondary antibodies (1:5000) were added. Bands were subsequently visualized using the enhanced plus chemiluminescence assay (Pierce, USA). Measurement of the bands was conducted on an ImageQuant LAS 4000 mini.
Cell proliferation
In brief, cells were treated with 300 μg/ml hyaluronidase and control medium. Then, equal numbers of cells (2000 cells/well) were seeded into 96-well plates for the proliferation experiment. The proliferation of MDA-MB-231 and BT-549 cells was measured via CCK-8 assay (KeyGen Biotech,China) according to the manufacturer’s protocol.
CD44 Cross-linking
Cells were treated with different concentrations of hyaluronidase for 0.5 h, then the cells were washed 3 times with ice-cold PBS (20 mM sodium phosphate, 0.15 M NaCl, pH 8.0). CD44 cross-linking was performed by incubation with 2 mM bis (sulfosuccinimidyl) suberate (BS3) (Pierce, USA) for 30 min and quenched by incubation with 20 mM Tris, pH 7.6 for 15 min at room temperature. Cells were washed twice with PBS and lysed with cell lysis buffer.
For antibody-mediated CD44-crosslinking. BrCas cells were incubated for 90 min at 37 °C with rat monoclonal CD44 antibody (10 mg/ml) (clone IM7, Cat #14-0441-86). After three washes, cells were incubated with 1 mg/ml of goat anti-rat IgG-Fc (Cat #31226) for 60 min at 37 °C and then subjected to cell lysis.
Cell migration and invasion assays
To evaluate the migration and invasion abilities of BrCas cells, Transwell assays were performed. In brief, MCF-7, T-47D, MDA-MB-231 and BT-549 cells were suspended in medium containing 5% FBS after transfection. In addition, 3 × 104 cells were seeded into the upper chamber of an 8-μm pore size insert with or without Matrigel (BD Biosciences, USA). The chambers were deposited in a 24-well plate with 600 μl of 20% FBS medium. After 24 h’s incubation, the cells were fixed with 4% paraformaldehyde (Beyotime, China) and stained with crystal violet (Beyotime, China). After removing the cells on the upper surface of the chamber, the penetrated cells were captured and the number of cells was counted by Image J software at 200× magnification in five random fields under a microscope.
Immunohistochemistry (IHC) and staining evaluation
Formalin-fixed paraffin-embedded human BrCas tissues were obtained from Shanghai Superchip Biotech (HBreD055CD01). The expression of p-Moesin in the tissue chip of the cohort of 55 tissues was examined by IHC. The tissue chip was incubated with rabbit monoclonal antibody against human p-Moesin (Abcam, ab177943). Then the sections of tissue chip were detected by Outdo Biotech (Shanghai, China).
The expression of Moesin was scored with intensity of staining and the percentage of the cells of interest staining. We divided the intensity of staining into 4 groups: 0 (–), 1 (+), 2 (++), and 3(+++). The (–), (+), (++), (+++) were defined as no staining, weak staining, moderate staining and intense staining. Then we ranked the percentage of positive staining into 4 categories: 0 (0%), 1 (1–29%), 2 (30–69%), and 3 (≥ 70%) as shown in Additional file
1: Figure S4. The IHC scores are obtained by multiplying the above two scores. The final figures were created by Graphpad 7.
Statistical analysis
All data are presented as the mean ± SD and were analyzed with GraphPad Prism 7 and SPSS v23 software. The student’s t-test was used to identify the differences between the treated groups and their controls. IHC scores among three groups were analyzed with the non-parametric alternative to ANOVA. A P value < 0.05 was considered statistically significant in the text and figures (*P < 0.05, **P < 0.01, ***P < 0.001).
Discussion
Receptor cross-linking is often considered to be a hallmark of malignant tumor initiation and progression, during which downstream signal pathways are usually activated that affect cell function [
22‐
24]. CD44, the main receptor for HA, is a well-accepted molecular marker for cancer stem cells. Data have stated that CD44 is involved in tumor-initiating that includes CD44 self-interaction and downstream signal activation [
25]. However, the mechanism of CD44 clustering in cancer progression is not well illustrated. In this study, we demonstrate for the first time that CD44 cross-linking promotes BrCas cell aggression by regulating the downstream ERM proteins, particularly through p-Moesin. Correspondingly, the decrease of p-Moesin could inhibit the BrCas cells migration and invasion after disrupting CD44 cross-linking, suggesting a CD44 clustering-p-Moesin pathway that regulates BrCas malignancy (Additional file
5: Figure S5).
Tumor cell metastasis is one of the features of most lethal tumors [
26]. Studies have found that CD44 is overexpressed in metastatic BrCas [
27] and its multiple spliced forms have also been shown to be closely associated with BrCas cell metastasis [
28]. Besides overproduction, CD44 cross-linking is also believed to induce cancer cell adhesion and migration [
13]. However, a recent study stated that CD44 clustering in breast epithelial cells could reduce cell growth [
29]. These studies suggest that the functions of CD44 cross-linking are diverse and unknown details are needed to be explored.
As reported, CD44 molecules are dispersed over the cell surface under homeostatic conditions, whereas clustering could be induced by aberrant HA deposition in pathological microenvironments [
14,
29]. Intriguingly, such receptors self-linking could be reversed following the degradation process by abnormal metabolites, such as hyaluronidase. The significances of CD44 receptors self-aggregation and de-cross- linking are being investigated. Some observations have suggested that the disruption of CD44 self-linking could inhibit BrCas cells migration and invasion [
30,
31]. However, the mechanisms involved are not elucidated thoroughly, including the downstream molecules closely connected to CD44 or intracellular skeletal complex beneath the CD44 receptors.
It is well known that ERM complex (Ezrin, Radixin and Moesin) are cytoskeletal molecules connected to CD44 C-terminal domain and are believed to be closely related to cancer malignancy. Due to their structure homology, the three members are often studied as a whole [
32]. However, a growing body of evidence proves that ERM proteins perform distinct functions during different biological processes [
19,
33‐
35]. In our study, we found that CD44 cross-linking could cause Moesin phosphorylation without changing its expression. At the same time, Ezrin and Radixin, two other components of the ERM complex showed no alterations in quantity and activity, suggesting that CD44 cross-linking plays its downstream role mainly through p-Moesin in BrCas. Previous findings indicated that HA can significantly enhance the invasiveness of glioma cells by promoting the binding of CD44 and Moesin [
36]. Nevertheless, in our current study, we found that HA increases BrCas malignancy through inducing CD44 receptors self-linking, thus triggering downstream Moesin’s phosphorylation, rather than simply binding to CD44. Moreover, our loss-and-gain-of-function experiment proved that removing ligand (HA) with hyaluronidase to destroy CD44 cross-linking obviously inhibited p-Moesin expression, while p-Moesin was rescued following the addition of an antibody that re-induced CD44 cross-linking. Since CD44 clustering does not affect the expression of Moesin, we knocked down Moesin to downregulate p-Moesin. We observed that the promoting effect of CD44 clustering on BrCas cell migration could be halted after the Moesin knockdown. Taken together, these data suggested that p-Moesin may be indispensable in BrCas cell aggression caused by CD44 cross-linking and may have potential clinical application value.
To further verify the clinical significance of p-Moesin in BrCas, we determined its expression level with a sample cohort. Our IHC results showed that p-Moesin is highly expressed in primary BrCas compared with normal tissue. Additionally, we also observed that the p-Moesin expression in metastases is higher than that in primary tumors, suggesting that p-Moesin is clinically associated with the induction of metastasis in BrCas. Furthermore, through analyzing the TCGA database, we found that there was no significant difference in Moesin expression between BrCas and adjacent tissues, as well as no correlation of Moesin with BrCas patients’ poor prognosis. Collectively, our study highlighted that p-Moesin rather than Moesin, could be applied as a potential target for BrCas therapy.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (81572821, 81672843, 81702852, 81872357, 81974445 and 81974446), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20171924), Program of Shanghai Leading Talents (2013-038), Doctor Innovation Fund of Shanghai Jiaotong University School of Medicine (BXJ201944) and Shanghai Pujiang Program (2019PJD037).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.